Shubham Pant, M.D., MBBS

Peer-Reviewed Articles

1. Lee MS, Kaseb AO, Pant S. The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers. Clin Cancer Res 29(17):3267-3274, 2023. e-Pub 2023. PMID: 37092904.
2. Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. J Clin Oncol 41(25):101200JCO2300434, 2023. e-Pub 2023. PMID: 37099736.
3. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
4. Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y, RAGNAR Investigators. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 24(8):925-935, 2023. PMID: 37541273.
5. Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Res Sq, 2023. e-Pub 2023. PMID: 37609177.
6. Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent with Neoadjuvant Therapy on Physical Function of Patients with Pancreatic Cancer: The Pancfit Randomized Clinical Trial. Ann Surg 278(1):22-30, 2023. e-Pub 2023. PMID: 37026453.
7. Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S, HERIZON-BTC-01 study group. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol 24(7):772-782, 2023. e-Pub 2023. PMID: 37276871.
8. Pant S, Hamilton E, Ulahannan SV, Strauss JF, Braiteh FS, Huang M, Liaw DCH. Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors. Cancer 129(12):1919-1929, 2023. e-Pub 2023. PMID: 36970876.
9. Subbiah V, Pant S. Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!. Ann Oncol 34(6):503-506, 2023. PMID: 37295905.
10. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. e-Pub 2023. PMID: 37311055.
11. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. e-Pub 2023. PMID: 37339271.
12. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. PMID: 37058010.
13. Gencel-Augusto J, Su X, Qi Y, Whitley EM, Pant V, Xiong S, Shah V, Lin J, Perez E, Fiorotto ML, Mahmud I, Jain AK, Lorenzi PL, Navin NE, Richie ER, Lozano G. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discov 13(5):1230-1249, 2023. PMID: 37067911.
14. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
15. Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer. e-Pub 2023. PMID: 37119430.
16. Pant V, Sun C, Lozano G. Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death Differ 30(4):897-905, 2023. e-Pub 2023. PMID: 36755072.
17. Newhook TE, Vreeland TJ, Griffin JF, Tidwell RSS, Prakash LR, Koay EJ, Ludmir EB, Smaglo BG, Pant S, Overman M, Wolff RA, Ikoma N, Maxwell J, Kim MP, Lee JE, Katz MHG, Tzeng CD. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg 277(3):484-490, 2023. e-Pub 2022. PMID: 36649067.
18. Pant S, Dragovich T, Lieu C, Jimeno A, Kundranda M, Menter D, Tchaparian E, Chen YC, Kopetz S. Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Invest New Drugs 41(1):25-34, 2023. e-Pub 2022. PMID: 36331676.
19. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
20. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2022. PMID: 36423446.
21. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
22. Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol 23(12):1558-1570, 2022. e-Pub 2022. PMID: 36400106.
23. Kang Y, Deng J, Ling J, Li X, Chiang YJ, Koay EJ, Wang H, Burks JK, Chiao PJ, Hurd MW, Bhutani MS, Lee JH, Weston BR, Maitra A, Ikoma N, Tzeng CD, Lee JE, DePinho RA, Wolff RA, Pant S, McAllister F, Katz MH, Fleming JB, Kim MP. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest 132(24), 2022. e-Pub 2022. PMID: 36282600.
24. Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys 114(3):444-453, 2022. e-Pub 2022. PMID: 35863672.
25. Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs 40(5):990-1000, 2022. e-Pub 2022. PMID: 35767205.
26. Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. Cancer Discov 12(10):2330-2349, 2022. e-Pub 2022. PMID: 35849783.
27. Massard C, Cassier PA, Azaro A, Anderson B, Yuen E, Yu D, Oakley G, Benhadji KA, Pant S. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol 90(4):335-344, 2022. e-Pub 2022. PMID: 36030462.
28. Pant S, Thomas S, Loganathan S, Valapa RB. 3D bioprinted poly(lactic acid)/mesoporous bioactive glass based biomimetic scaffold with rapid apatite crystallization and in-vitro Cytocompatability for bone tissue engineering. Int J Biol Macromol 217:979-997, 2022. e-Pub 2022. PMID: 35908677.
29. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
30. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol 6:e2100512, 2022. PMID: 35834760.
31. Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res 28(11):2229-2236, 2022. PMID: 35312753.
32. Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res 41(1):189, 2022. e-Pub 2022. PMID: 35655320.
33. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
34. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs 40(2):461, 2022. PMID: 34705134.
35. Cazacu IM, Pant S, Bhutani MS. Precision Oncology With Germline and Somatic Sequencing in Pancreatic Cancer: The Time Is Now. Pancreas 51(4):295-296, 2022. PMID: 35775636.
36. Panettieri E, Maki H, Kim BJ, Kang HC, Cox V, Vega EA, Mizuno T, Pant S, Javle M, Vauthey JN, Kawaguchi Y. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol 40:101696, 2022. e-Pub 2021. PMID: 34995974.
37. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
38. Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol 6:e2100197, 2022. PMID: 35171660.
39. Zucali PA, Lin CC, Carthon BC, Bauer TM, Tucci M, Italiano A, Iacovelli R, Su WC, Massard C, Saleh M, Daniele G, Greystoke A, Gutierrez M, Pant S, Shen YC, Perrino M, Meng R, Abbadessa G, Lee H, Dong Y, Chiron M, Wang R, Loumagne L, Lépine L, de Bono J. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. J Immunother Cancer 10(1), 2022. PMID: 35058326.
40. Douglas JE, Liu S, Ma J, Wolff RA, Pant S, Maitra A, Tamm EP, Bhosale P, Katz MHG, Varadhachary GR, Koay EJ. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer 22(1):14, 2022. e-Pub 2022. PMID: 34980020.
41. Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5(1):99, 2021. e-Pub 2021. PMID: 34853384.
42. Pant S, Moyers JT, Naing A. Letter to the editor from Pant et al. J Immunother Cancer 9(11):e003991. e-Pub 2021. PMID: 34725215.
43. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol 12(5):2268-2274, 2021. PMID: 34790391.
44. Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol 16(5):569-589, 2021. e-Pub 2021. PMID: 34559360.
45. Azaro A, Massard C, Tap WD, Cassier PA, Merchan J, Italiano A, Anderson B, Yuen E, Yu D, Oakley G, Benhadji KA, Pant S. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Invest New Drugs 39(4):1089-1098, 2021. e-Pub 2021. PMID: 33686452.
46. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther 38(8):4581-4591, 2021. e-Pub 2021. PMID: 34241781.
47. Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med 10(15):5041-5050, 2021. e-Pub 2021. PMID: 34250759.
48. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
49. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res 27(11):3050-3060, 2021. e-Pub 2021. PMID: 33771853.
50. Pant S. Regarding HER2-Amplified Biliary Tract Cancer. Oncologist. e-Pub 2021. PMID: 34156737.
51. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol 4(2):45-52, 2021. e-Pub 2021. PMID: 35663531.
52. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg 273(4):806-813, 2021. e-Pub 2019. PMID: 31274655.
53. Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, Brenner A, Cook N, Lopez J, Pant S, Frankel A, Schmid P, Moore K, McCulloch W, Grimmer K, O'Farrell M, Kemble G, Burris H. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine 34:100797, 2021. e-Pub 2021. PMID: 33870151.
54. Coveler AL, Mizrahi J, Eastman BM, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S, Precision Promise Consortium. Pancreas Cancer-Associated Pain Management. Oncologist. e-Pub 2021. PMID: 33885205.
55. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. e-Pub 2021. PMID: 33909232.
56. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res 27(5):1247-1255, 2021. e-Pub 2020. PMID: 33115815.
57. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
58. Lee MS, Pant S. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. Am Soc Clin Oncol Educ Book 41:1-13, 2021. PMID: 33929876.
59. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs 39(1):182-192, 2021. e-Pub 2020. PMID: 32910338.
60. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34250391.
61. Surana R, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol 1342:259-272, 2021. PMID: 34972968.
62. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep 10(1):22087, 2020. e-Pub 2020. PMID: 33328484.
63. Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S. Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist 25(11):e1628-e1639, 2020. e-Pub 2020. PMID: 32537847.
64. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer 123(11):1590-1598, 2020. e-Pub 2020. PMID: 32913286.
65. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6):e001073, 2020. PMID: 33229506.
66. Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res 26(22):5830-5842, 2020. e-Pub 2020. PMID: 32816889.
67. Perri G, Prakash L, Malleo G, Caravati A, Varadhachary GR, Fogelman D, Pant S, Koay EJ, Herman J, Maggino L, Milella M, Kim M, Ikoma N, Tzeng CW, Salvia R, Lee JE, Bassi C, Katz MHG. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Ann Surg Oncol 27(10):3939-3947, 2020. e-Pub 2020. PMID: 32266574.
68. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2), 2020. PMID: 33097611.
69. Pant S, Lee MS. Barriers to Pancreatic Clinical Trials Enrollment. Oncology (Williston Park) 34(10), 2020. PMID: 33090379.
70. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg 155(9):832-839, 2020. PMID: 32667641.
71. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 9(15):5406-5415, 2020. e-Pub 2020. PMID: 32519420.
72. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol:JCO2001364. e-Pub 2020. PMID: 32755482.
73. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg 271(6):996-1002, 2020. e-Pub 2019. PMID: 31895709.
74. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 20(3):501-504, 2020. e-Pub 2020. PMID: 31932214.
75. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
76. Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol 11(1):55-60, 2020. PMID: 32175105.
77. Mizrahi J, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol 1244:93-106, 2020. PMID: 32301012.
78. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol 20(11):1544-1555, 2019. e-Pub 2019. PMID: 31563517.
79. Roberts K, Demner-Fushman D, Voorhees EM, Hersh WR, Bedrick S, Lazar AJ, Pant S, Meric-Bernstam F. Overview of the TREC 2019 Precision Medicine Track. Text Retr Conf 1250, 2019. PMID: 34849512.
80. Pant S, Maitra A, Yap TA. PARP inhibition - opportunities in pancreatic cancer. Nat Rev Clin Oncol 16(10):595-596, 2019. PMID: 31332344.
81. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer 136:158, 2019. e-Pub 2019. PMID: 31445783.
82. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
83. Bhutani MS, Cazacu IM, Luzuriaga Chavez AA, Singh BS, Wong FCL, Erwin WD, Tamm EP, Mathew GG, Le DB, Koay EJ, Taniguchi CM, Minsky BD, Pant S, Tzeng CD, Koong AC, Varadhachary GR, Katz MHG, Wolff RA, Fogelman DR, Herman JM. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE 4(5):223-225, 2019. e-Pub 2019. PMID: 31065616.
84. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res 21(3):e10348, 2019. e-Pub 2019. PMID: 30869638.
85. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914034.
86. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
87. Aghajanian C, Bell-McGuinn KM, Burris HA, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs 36(6):1016-1025, 2018. e-Pub 2018. PMID: 29611022.
88. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell 34(5):775-791.e3, 2018. PMID: 30423297.
89. Pant S, Hubbard J, Martinelli E, Bekaii-Saab T. Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Crit Rev Oncol Hematol 130:78-91, 2018. e-Pub 2018. PMID: 30196915.
90. Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK. Genetic landscape of gallbladder cancer: Global overview. Mutat Res 778:61-71, 2018. e-Pub 2018. PMID: 30454684.
91. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 41(6):284-291, 2018. PMID: 29668571.
92. Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res 24(14):3253-3262, 2018. e-Pub 2018. PMID: 29636360.
93. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 120:137-141, 2018. e-Pub 2018. PMID: 29748008.
94. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
95. Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Craig Lockhart A, Goodman D, Huebner D, Mould DR, Venkatakrishnan K. Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. Invest New Drugs 36(2):240-247, 2018. e-Pub 2017. PMID: 28819760.
96. Zhou X, Pant S, Nemunaitis J, Craig Lockhart A, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargfrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. Invest New Drugs 36(2):248-258, 2018. e-Pub 2017. PMID: 28852909.
97. Lam M, Pant S, Yap TA. Combination drug development in BRAF mutant colorectal cancer. Oncoscience 5(3-4):51-53, 2018. e-Pub 2018. PMID: 29854866.
98. Roberts K, Demner-Fushman D, Voorhees EM, Hersh WR, Bedrick S, Lazar AJ, Pant S. Overview of the TREC 2017 Precision Medicine Track. Text Retr Conf 26, 2017. PMID: 32776021.
99. Pant S, Patel M, Kurkjian C, Hemphill B, Flores M, Thompson D, Bendell J. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Invest 35(7):1-10, 2017. e-Pub 2017. PMID: 28662341.
100. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. e-Pub 2017. PMID: 28729355.
101. Burris HA, Kurkjian CD, Hart L, Pant S, Murphy PB, Jones SF, Neuwirth R, Patel CG, Zohren F, Infante JR. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemother Pharmacol. e-Pub 2017. PMID: 28601972.
102. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol 39(6):614-618, 2016. e-Pub 2014. PMID: 25068471.
103. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol 78(5):921-927, 2016. e-Pub 2016. PMID: 27681579.
104. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol 34(29):3562-3569, 2016. e-Pub 2016. PMID: 27528724.
105. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol 61:31-40, 2016. e-Pub 2016. PMID: 27688102.
106. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase II Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther 24(6):1150-8, 2016. e-Pub 2016. PMID: 27039845.
107. Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Cancer Chemother Pharmacol 77(6):1275-83, 2016. e-Pub 2016. PMID: 27151157.
108. Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BK, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ES, Chan EM, Bendell JC. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer 56:1-9, 2016. e-Pub 2016. PMID: 26798966.
109. Tolaney SM, Beeram M, Beck JT, Conlin AK, Dees EC, Dickler MN, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Turner PK, Cai N, Chan EM, Pant S, Becerra C, Kalinsky K, Puhalla S, Rexer BN, Burris HA, Goetz MP. A Phase 1b Study of Abemaciclib, an inhibitor of CDK4 and CDK6, in Combination with Endocrine and HER2-targeted Therapies for Patients with Metastatic Breast Cancer. Annals of Oncology 27(6):v552-v587, 2016.
110. Phan M, Jones S, Jenkins J, Pant S, Khawandanah M. Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases. Case Rep Oncol Med 2016:9604982, 2016. e-Pub 2016. PMID: 27579203.
111. Khawandanah M, Baxley A, Pant S. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. J Oncol Pharm Pract 21(3):232-7, 2015. e-Pub 2014. PMID: 24627343.
112. Bendell JC, Patel MR, Infante JR, Kurkjian CD, Jones SF, Pant S, Burris HA, Moreno O, Esquibel V, Levin W, Moore KN. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer 121(7):1056-63, 2015. e-Pub 2014. PMID: 25411085.
113. Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol 55(4):392-400, 2015. e-Pub 2014. PMID: 25449654.
114. Ahmad B, Pierson N, Adnan MM, Phan M, Jenkins J, Pant S, Cherry M, Khawandanah M. Distant skin metastases as primary presentation of gastric cancer. J Community Support Oncol 13(4):156-8, 2015. PMID: 26102608.
115. Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One 10(2):e0118933, 2015. e-Pub 2015. PMID: 25723399.
116. Bendell JC, Jones SF, Hart L, Pant S, Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, Thompson D, Infante JR. A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. Cancer Invest 33(10):477-82, 2015. e-Pub 2015. PMID: 26460795.
117. Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) 7(3):1499-542, 2015. e-Pub 2015. PMID: 26266422.
118. Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 14(5):398-402, 2014. e-Pub 2014. PMID: 25278310.
119. Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 25(7):1416-21, 2014. e-Pub 2014. PMID: 24737778.
120. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 120(12):1780-6, 2014. e-Pub 2014. PMID: 24633933.
121. Pant S, Burris HA, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs 32(1):87-93, 2014. e-Pub 2013. PMID: 23525756.
122. Kurkjian N, Kurkjian C, Pant S, Tucker P. Psycho-oncology: a brief history and case study. J Okla State Med Assoc 106(12):471-4, 2013. PMID: 24620412.
123. Cherry MA, Bhardwaj H, Hopps S, Srour S, Pant S. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. J Oncol Pharm Pract 19(3):261-4, 2013. e-Pub 2012. PMID: 23135805.
124. Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract 19(3):222-7, 2013. e-Pub 2012. PMID: 23135806.
125. Landmann A, Makipour JJ, Morgan A, Postier R, Pant S, Liu C, Anderson J. Image of the month. Extramedullary plasmacytoma. JAMA Surg 148(1):101-2, 2013. PMID: 23324848.
126. Alinari L, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RA. Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male. Head Neck Pathol 6(4):496-501, 2012. e-Pub 2012. PMID: 22711054.
127. Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol 70(1):49-56, 2012. e-Pub 2012. PMID: 22729159.
128. Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. Br J Haematol 148(4):623-6, 2010. e-Pub 2009. PMID: 19821825.
129. Pant S, Ramaswamy B. Association of major stressors with elevated risk of breast cancer incidence or relapse. Drugs Today (Barc) 45(2):115-26, 2009. PMID: 19343231.
130. Pant S, Chilukuri MP, Ramaswamy B. Docetaxel for the post-surgery treatment of patients with node-positive breast cancer. Ther Clin Risk Manag 4(2):419-24, 2008. PMID: 18728853.
131. Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26(9):1567-9, 2008. PMID: 18349415.
132. Pant S, Shapiro CL. Aromatase inhibitor-associated bone loss: clinical considerations. Drugs 68(18):2591-600, 2008. PMID: 19093701.
133. Pant S, Ozer H. New agents in the treatment of ovarian cancer. Managed Care Oncology(4):26-28, 2008.
134. Pant S, Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 13(8):877-85, 2007. PMID: 17640590.
135. Kamble R, Pant S, Selby GB, Kharfan-Dabaja MA, Sethi S, Kratochvil K, Kohrt N, Ozer H. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion 45(6):874-8, 2005. PMID: 15934984.

Other Articles

1. Hopps S, Kurkjian C, Pant S A Review of PARP Inhibitors in Clinical Development. Journal of Hematology/Oncology Pharmacy 2(1):18-28, 2012.
2. Hopps S, Pant S, Update on PARP Inhibitors in Breast Cancer. The Oncology Pharmacist 4(3):22, 2011.
3. Charania R, Pant S, Morgal S, Borders E Treatment of Metastatic Colon cancer: A Multidiciplinary Approach. Journal of Multidisciplinary Cancer Care 2(3):18-23, 2009.
4. Pant, Ozer H New Agents in the Treatment of Ovarian Cancer. Managed Care Oncology 4:26-28, 2008.
5. Pant S, Miguel-A Villalona-Calero Lung Cancer Highlights of ASCO 2007. Lung Cancer Frontiers(31):5-7, 2007.
6. Pant S, Ozer H Managing Hematologic Toxicities, A Peer Viewpoint. Journal of Supportive Oncology 2(1):71-2, 2004.

Abstracts

1. Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C-Y, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ). PO.CT02.02 - Phase II Clinical Trials 2, 2022.
2. J. Moyers, D. Nguyen, D.S. Hong, E. Ileana Dumbrava, S. Fu, D. Karp, A. Naing, S.Pant, F. Janku, S. Piha-Paul, J. Rodon, V. Subbiah, A.M. Tsimberidou, F. Meric-Bernstam, T. Yap. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Congress 2021, 2021.
3. E.R. Parra, M. Adriani, C. Freitas Pinto Lima, J. Li, C. Haymaker, R. Parikh, E. Bernicker, D. Davar, A. Chaudhry, A. Stevenson, C. Badham, G. Fyvie, M. Chisamore, S. Pant. Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab. ESMO Congress 2021, 2021.
4. E. Borazanci, M.N. Al Hallak, J.P. Eder, T. Golan, S. Pant, R. Perets, G. Markel, M. Schickler, H. Reuveni, L. Jin, B. Liang. A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer. ESMO Congress 2021, 2021.
5. M.L. Johnson, E. Gort, S. Pant, M.P. Lolkema, M. Sebastian, M. Scheffler, J. Hwang, U. Dünzinger, K. Riemann, T. Kitzing, P.A. Jänne. A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis. ESMO Congress 2021, 2021.
6. Omar Alhalabi, Aung Naing, Roman Groisberg, Andrew Hahn, Shizhen Zhang, Samantha C. Berkey, Apostolia M. Tsimberidou, Jordi Rodon, Timothy A. Yap, Shubham Pant, Amishi Y. Shah, Amado Zurita-Saavedra, Nizar Tannir, Funda Meric-Bernstam, Vivek Subbiah.. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations, 2021.
7. Niamh Coleman, Charles Abbot, Neeta Somaiah, Sarina Piha-Paul, Shubham Pant, Jordi Rodon, S. Greg Call, Sean Boyle, Funda Meric-Bernstam, Filip Janku. Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST), 2021.
8. Chia-Chi Lin, Paolo Zucali, Bradley Carthon, Todd M. Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Monsoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Johann De Bono, Johann De Bono.. Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study, 2021.
9. Mohamed Alaa Gouda, Helen J Huang, Sarina Anne Piha-Paul, S. Greg Call, Daniel D. Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Pant S, Apostolia Maria Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Funda Meric-Bernstam, Filip Janku. Genomically Informed Longitudinal Monitoring of Circulating Tumor DNA (ctDNA) Predicts Outcomes of Cancer Therapy. J Clin Oncol ASCO Meeting 2020 38, 2020.
10. Ishwaria Mohan Subbiah, Aman Buzdar, Ecaterina Elena Ileana Dumbrava, Siqing Fu, Filip Janku, Daniel D. Karp, Aung Naing, Pant S., Jordi Rodon, Apostolia Maria Tsimberidou, Timothy A Yap, Vivek Subbiah, Funda Meric-Bernstam, David S. Hong. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. J Clin Oncol ASCO Annual Meeting 2020 38, 2020.
11. Omar Alhalabi, Andrew W Hahn, Funda Meric-Bernstam, Aung Naing, Sarina Anne Piha-Paul, Filip Janku, Pant S, Timothy A Yap, David S. Hong, Siqing Fu, Erick Campbell, Hung Le, Amishi Yogesh Shah, Matthew T Campbell, Nizar M. Tannir, Arlene O. Siefker-Radtke, Jianjun Gao, Jason Roszik, Vivek Subbiah. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. J Clin Oncol ASCO Meeting 2020 38, 2020.
12. Ryan Huey, Goldy George, Penny Phillips, Revenda White, Siqing Fu, Filip Janku, Daniel D. Karp, Aung Naing, Sarina Anne Piha-Paul, Vivek Subbiah, Apostolia Maria Tsimberidou, Pant S, Timothy A Yap, Jordi Rodon Ahnert, Funda Meric-Bernstam, Ya-Chen T. Shih, David S. Hong. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. J Clin Oncol ASCO Meeting 2020 38, 2020.
13. Eelke Gort, Melissa Lynne Johnson, Jimmy J. Hwang, Pant S, Ulrich Dünzinger, Kathrin Riemann, Thomas Kitzing, Pasi A. Janne. A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors. J Clin Oncol, 2020 ASCO Meeting 38, 2020.
14. Elizabeth Charlotte Moser, Sarah E. Hoffe, Jessica Frakes, Todd Anthony Aguilera, Mona Karim, Lauren Elizabeth Colbert, Shalini Moningi, Ching-Wei David Tzeng, Peter F. Thall, Pant S, Manoop S. Bhutani, Melissa Brookes, Jon Holmlund, Joseph M. Herman, Cullen M. Taniguchi. Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer. J Clin Oncol, 2020 ASCO Meeting 38, 2020.
15. Pant, S.. Erdafitinib for advanced solid tumors: A phase 2, open-label efficacy and safety study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations, 2020.
16. Pant, S.. Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC, 2020.
17. Andrew W Hahn, Omar Alhalabi, Funda Meric-Bernstam, Aung Naing, Eric Jonasch, Pavlos Msaouel, Sarina Anne Piha-Paul, David S. Hong, Pant S, Timothy A Yap, Erick Campbell, Hung Le, Nizar M. Tannir, Jason Roszik, Vivek Subbiah. Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, ASCO Meeting 2020 38, 2020.
18. Pant, S., Imke Mulder, Amishi Yogesh Shah, Pavlos Msaouel, Mehmet Altan, John Weinberg, Alex Stevenson, Funda Meric-Bernstam, Timothy A Yap, Vivek Subbiah, Jordi Rodon Ahnert. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. J Clin Oncol; Proceedings of the 2019 ASCO Annual Meeting, 2019.
19. Pant, S. Johanna C. Bendell, Ryan J. Sullivan, Geoffrey Shapiro, Michael Millward, Gu Mi, Eunice Yuen, Melinda D. Willard, Dan Wang, Sajan Joseph, William T. McMillen, Shripad V. Bhagwat, Ramon Velasquez Tiu, Manish R. Patel. A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts. J Clin Oncol, Annual Meeting 2019 SITC, 2019.
20. Pant, S., Lamar, M., Kazakin, J., Savage, R, Schwartz, B., Hall, T. The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751. Mol Cancer Ther, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2019.
21. Aparna Hegde, MD; Priyamvada Jayaprakash, PhD; Elizabeth Sumner; Di Nguyen; Hira Zain; Sarina A. Piha-Paul, MD; Daniel Karp; Jordi Rodon; Pant, S., Siqing Fu, MD, PhD; Ecaterina I.. A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. SITC Annual Meeting 2019, 2019.
22. Z.A. Wainberg, J.C. Sachdev, T. Bauer, Pant S., S. Chawla, N. Marina, H. Xiang, W. Deng, M. Schmidt, A. Patnaik, P. LoRusso. FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab. Annals of Oncol, ESMO Congress 2019, 2019.
23. A. Ocean, M. Noel, A. Wang-Gillam, S. Chawla, V. Chung, Pant S., R. Korn, G. Del Priore, V. Picozzi. Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in Heavily Pre-Treated PDAC Patients. Annals of Oncol, ESMO Congress 2019, 2019.
24. A. Naing, F. Meric-Bernstam, D. Karp, J.A. Rodon, S.A. Piha-Paul, V. Subbiah, D.S. Hong, S. Pant, S. Fu, F. Janku, T.A. Yap, A.M. Tsimberidou, E.E. Ileana Dumbrava, R.R. Colen, K.R. Hess, M.T. Campbell, S. Tu, C. Jimenez, M.A. Habra, G.R. Varadhachary. Pembrolizumab in Advanced Rare Cancers. Annals of Oncology, ESMO Congress 2019, 2019.
25. C. Mohindroo, J. Rogers, M. Hasanov, J. Mizrahi, M. Overman, G., R. Varadhachary, R. Wolff, M. Javle, D. Fogelman, <b>S. Pant,</b>. A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer. ASCO Annual Meeting 2019, 2019.
26. Merve Hasanov, Chirayu Mohindroo, Jane Rogers, Laura Prakash, Michael J. Overman, Gauri Rajani Varadhachary, Robert A. Wolff, Milind M. Javle, David R. Fogelman, Pant S., Matthew H. G. Katz, Michael Paul Kim, Ching-Wei David Tzeng, Florencia McAllister. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol, ASCO Annual Meeting 2019, 2019.
27. Jasgit C. Sachdev, Todd Michael Bauer, Sant P. Chawla, Pant, S. , Amita Patnaik, Zev A. Wainberg, Sandeep P. Inamdar, Neyssa Marina, Stefanie Sun, Maike Schmidt, Hong Xiang, Patricia LoRusso. Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. J Clin Oncol, ASCO Annual Meeting 2019, 2019.
28. Deirdre Jill Cohen, Pant S., Bert O'Neil, Jill Marinis, James Winnberg, Christoph Matthias Ahlers, Justin Callaway, Chetan Rathi, Andre Acusta, Adeline Verticelli, John Bertin, James F . Smothers. A phase I/study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors. J Clin Oncol. ASCO Annual Meeting 2019, 2019.
29. Filip Janku, Shiraj Sen, Pant S. , Lindsay Bramwell, Vivek Subbiah, Tracey Way, Milind M. Javle, Cassie Stone, Bhumika Prajapati, Shinji Hagiwara, Mary Johansen, Timothy Madden, Gary Maier, Ruth Ann Subach, Kazunori Saeki, Takeaki Suzuki, David S. Wages, Catherine A. Wheeler, Gerald Steven Falchook. Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors. J Clin Oncol, ASCO Annual Meeting 2019, 2019.
30. Tyler J. Moss, Jordi Rodon Ahnert, Holly D. Oakley, Michael Kahle, Daniel D. Karp, S. Pant, Jeena Jacob, Victoria M. Raymond, Richard B. Lanman, Lawrence Kwong, Mark Routbort, Nital Soni, Jerry Huang, Milind M. Javle, Funda Meric-Bernstam. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. J Clin Oncol, ASCO Annual Meeting 2019, 2019.
31. Ryan Huey, Goldy George, Penny Phillips, Revenda White, Siqing Fu, Filip Janku, Daniel D. Karp, Aung Naing, Sarina Anne Piha-Paul, Vivek Subbiah, Apostolia Maria Tsimberidou, S. Pant, Timothy A Yap, Jordi Rodon Ahnert, Funda Meric-Bernstam, Ya-Chen T. Shih, David S. Hong. Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. J Clin Oncol, ASCO Annual Meeting 2019, 2019.
32. Timothy A Yap, Jordi Rodon Ahnert, Sarina Anne Piha-Paul, Siqing Fu, Filip Janku, Daniel D. Karp, Aung Naing, Ecaterina Elena Ileana Dumbrava, S. Pant, Vivek Subbiah, Apostolia Maria Tsimberidou, David S. Hong, Kelsey Meagan Rose, Quanyun Xu, Christopher P. Vellano, Mikhila Mahendra, Philip Jones, Maria Emilia Di Francesco, Joseph R. Marszalek, Funda Meric-Bernstam. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Oncol, ASCO Annual Meeting 2019, 2019.
33. Timothy A Yap, Jordi Rodon Ahnert, Sarina Anne Piha-Paul, Siqing Fu, Filip Janku, Daniel D. Karp, Aung Naing, Ecaterina Elena Ileana Dumbrava, S. Pant, Vivek Subbiah, Apostolia Maria Tsimberidou, David S. Hong, Kelsey Meagan Rose, Quanyun Xu, Christopher P. Vellano, Mikhila Mahendra, Philip Jones, Maria Emilia Di Francesco, Joseph R. Marszalek, Funda Meric-Bernstam. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Onc, ASCO Annual Meeting 2019, 2019.
34. Roberto Carmagnani Pestana, Ishwaria Mohan Subbiah, Kenneth R. Hess, Le Huang, Shuang Liu, Kimberly Beltran, Holly Harrison, Angela Bryant, Jennifer Eshon, Timothy A Yap, S., Pant, Aung Naing, David S. Hong, Funda Meric-Bernstam, Vivek Subbiah. Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer who signed consent but were not treated in early-phase. J Clin Oncl, ASCO Annual Meeting 2019, 2019.
35. Katherine C. Kurnit, Funda Meric-Bernstam, Kenneth Hess, Robert L. Coleman, Priya Bhosale, Katerina Savelieva, Filip Janku, David Hong, Aung Naing, SPant S., Jordi Rodon, Timothy A. Yap, Anil K. Sood, Pamela T. Soliman, David M. Gershenson, Gordon B. Mills, Shannon N. Westin. Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations. AACR Annual Meeting 2019, 2019.
36. Andrea Wang-Gillam, Eileen Mary O'Reilly, Johanna C. Bendell, Zev A. Wainberg, Erkut Hasan Borazanci, Nathan Bahary, Mark H. O'Hara, Gregory Lawrence Beatty, S. Pant, Deirdre Jill Cohen, Stephen Leong, Muhammad Shaalan Beg, Kenneth H. Yu, T.R. Jeffry Evans, Thomas Seufferlein, Takuji Okusaka, Penny Phillips, Xuan Liu, Serena K Perna, Dung T. Le. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol, 2019 Gastrointestinal Cancers Symposium, 2019.
37. Jonathan Mizrahi, Jane Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri Rajani Varadhachary, Rachna T. Shroff, Linus Ho, David R. Fogelman, Kanwal Pratap Singh Raghav, Michael J. Overman, S. Pant. FOLFIRINOX in pancreatic cancer patients age 75 years or older. J Clin Oncol, 2019 Gastrointestinal Cancers Symposium, 2019.
38. Benny Johnson, Jonathan M. Loree, Van K. Morris, Arvind Dasari, S. Pant, Kanwal Pratap Singh Raghav, Scott Kopetz. Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer. J Clin Oncol, 2019 Gastrointestinal Cancers Symposium, 2019.
39. Pant, S. , V. Subbiah, J. Rodon, F. Janku, D. Hong, D. Karp, S. Piha-Paul, A.M. Tsimberidou, A. Naing, S. Fu, R.E. Savage, F. Chai, Y. Yu, K. Tith, R. Alfattal, B. Schwartz, F. Meric-Bernstam, T. Yap. A phase 1 dose escalation study of ARQ 751 in adult patients with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3 K mutations, PTEN-null, or other known actionable PTEN mutations". J Clin Oncol., AACR Annual Meeting 2018, 2018.
40. David R. Fogelman, MD; Michael Overman, MD; Robert Wolff; Milind Javle, MD;Pant, S. , MBBS; Gauri Varadhachary; Rachna T. Shroff; Ignacio Wistuba, MD; Carmelia M. Barreto, PhD; Renganayaki. A phase IIB study of Pembrolizumab plus BL-8040 in metastatic pancreatic cancer: Clinical outcomes and biological correlates, 2018.
41. Pant S, Spira AI, Cho BC, Goel S, Hoimes CJ, Alva AS, Balaraman R, Bauer TM, Lowry PA, Ramaekers RC, Siegel RD, Verner TL, Tannier NM, Faltaos D, Potvin D, Neuteboom STC, Christensen J, Chao RC, Kyriakopoulos. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). J Clin Oncol, 2018 ASCO Annual Meeting Proceedings 36, 2018.
42. Tannir NM, Naing A, Infante JR, Papadopoulos KP, Wong DJL, Korn M, Aljumaily R, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Van Vasselaer P, Leveque J, Oft M. Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol, 2018 ASCO Annual Meeting Proceedings 36, 2018.
43. Lam M, Pereira AAL, Loree JM, Advani SM, Overman MJ, Johnson A, Holla V, Khotskaya Y, Sanchez NS, Meric-Bernstam F,Kopetz S, Pant S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. J Clin Oncol, 2018 ASCO Annual Meeting Proceedings 36, 2018.
44. Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. J Clin Oncol, 2018 ASCO Annual Meeting Proceedings 36, 2018.
45. Mita MM, Mita AC, Chmielowski B, Hamilton EP, Pant S, Waltzman RJ, Rowinsky EK, Szarek M, Gonsales F, Kurth I, Andreu C, Busby R, Darst DM, Tavozoie SS, Tavozoie M, Postow MA. Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies . J Clin Oncol, 2018 ASCO Annual Meeting Proceedings 36, 2018.
46. Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F,Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. J Clin Oncol, ASCO Annual Meeting 2018, 2018.
47. Lam M, Pereira AA, Loree JM, Advani SM, Overman MJ, Bailey A, Johnson A, Holla V, Sanchez NS, Khotskaya Y, Meric-Bernstam F, Kopetz S, Pant S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. J Clin Oncol, 2018 ASCO Annual Meeting Proceedings 36(Suppl 4S), 2018.
48. R. Ferrarotto, B. Glisson, G. Blumenschein, D. Hong, S. Piha-Paul, J. Rodon Ahnert, S. Pant, A. Tsimberidou, F. Janku, A. Alshawa, D. Jain, M. Rejon, K. Hess, R. Colen, C. Lu, B. Stephen, C. Tapia, T. Mendoza, F. Meric-Bernstam, A. Naing. Efficacy of pembrolizumab in patients with adrenocortical carcinoma. Eur J Cancer;-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 2018.
49. R. Ferrarotto, B. Glisson, G. Blumenschein, D. Hong, S. Piha-Paul, J. Rodon Ahnert, S. Pant, A. Tsimberidou, F. Janku, A. Alshawa, D. Jain, M. Rejon, K. Hess, R. Colen, C. Lu, B. Stephen, C. Tapia, T. Mendoza, F. Meric-Bernstam, A. Naing. Efficacy of pembrolizumab in patients with cutaneous squamous cell carcinoma. Eur J Cancer;-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 2018.
50. Hecht JR, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Javle MM, Bendell JC, Pant S., Hung A, Van Vlasselaer P, Leveque J, Oft M, Papadopoulos KP. Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). J Clin Oncol, ASCO Annual Meeting 2018, 2018.
51. Subbiah V, Erwin W, Mawlawi O, Gonzalez-Lepera C, Tokura M, Kurman M, Liu H, Hong DS, Meric-Bernstam F, Pant .S, Johansen M, Madden T, Santos E, Ravizzini G. Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic (RIT) targeting P-cadherin, in advanced solid tumors. Cancer Res., AACR Annual Meeting 2018, 2018.
52. Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable. AACR Annual Meeting 2018, 2018.
53. Hecht JR, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Javle MM, Bendell JC, Pant S, Hung A, Van Vlasselaer P, Oft M, Papadopoulos KP. Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). J Clin Oncol.ASCO Gastrointestinal Cancers Symposium, 2018.
54. Ileana Dumbrava E, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Boraddus R, Routbort M, Pant S, TsimberidouA, Subbiah V, Hong DS, Rodon Ahnert J, Shaw K, Piha-Paul S, Meric-. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2018.
55. Vivek Subbiah, William Erwin, Osama Mawlawi, Carlos Gonzalez Lepera, Masahiko Tokura, Masayuki Kawakami, Holly Liu, Shubham Pant, Michele Rosner, Mary Johansen, Louis De Palatis, Thomas Myers, Linda Paradiso, Elmer Santos, Gregory Ravizzini. University of Texas MD Anderson Cancer Center, Houston, TX; Fujifilm Corporation, Tokyo, Japan; Fujifilm Pharmaceuticals, U.S.A., Inc., Cambridge, MA; Strategia Therapeutics, Inc., Houston, TX. Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic targeting P-cadherin, in advanced solid tumors. Cancer Res; Proceedings of the AACR Annual Meeting 2017 17(19), 2017.
56. Parseghian C, Patnana M, Bhosale P, Hess K, Kopetz S, Overman M, Naing A, Piha-Paul S, Subbiah V, Hong D, Le H, Pant S. Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy. Ann Oncol, ESMO World Congress on Gastrointestinal Cancer 2017 28(Suppl 3), 2017.
57. Varadhachary GR, Singh Raghav KP, Pant S, Janku F, Fu S, Hong DS, Piha-Paul SA, Colen RR, Subbiah V, Painter J, Tsimberidou AM, Stephen B, Karp DD, McQuinn L, Mendoza TR, Hess KR, Meric-Bernstam F, Naing A. Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Cancer of Unknown Primary. J. Clin Oncol, ASCO Annual Meeting 2017, 2017.
58. Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Higginbotham Koenig K, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. J Clin Oncol; Proceedings of the 2017 ASCO Annual Meeting, 2017.
59. Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong DS, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, Yap T, Javle M, Tapia C, Shaw KR, Eterovic K, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer). Mol Cancer Ther, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2017.
60. Mita M, Mita A, Chmielowski B, Postow M, Hamilton E, Pant S, Waltzman R, Rowinsky E, Szarek M, Gonsalves F, Kurth I, Andreu C, Pollack I, Mucida D, Tanqueco R, Tavozoie M. A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies. Mol Cancer Ther, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2017.
61. Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Higginbotham Koenig K, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. J Clin Oncol. 2017 ASCO Annual Meeting, 2017.
62. Pant S, Owonikoko TK, Diefenbach CS, Kim S, Chen Z, Towle EL, Pierce LJ, Mileham KF. Collection and utilization of oncology big data, 2017.
63. Naing A, Infante JR, Wong DJ, Korn MW, Aljumaily R, Papadopoulos K, Autio K, Pant S, Bauer TM, Drakaki A, Daver N, Hung A, Van Vlasselaer P, Brown G, Oft M, Tannier N. Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer. Ann Oncology, ESMO 2017 Congress, 2017.
64. Hecht JR, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio K, Wainberg ZA, Javle M, Bendell JC, Pant S, Hung A, Van Vlasselaer P, Brown G, Oft M, Papadopoulos K. Overall survival and immunologica responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX). Ann Oncol, ESMO 2017 Congress, 2017.
65. Hecht JR, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJL, Autio KA, Wainberg ZA, Javle MM, Bendell JC, Pant S, Hung A, Van Vlasselaer P, Brown GL, Oft M, Papadopoulos K. Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). ESMO World Congress on Gastrointestinal Cancer 2017, 2017.
66. Naing A, Wong DJL, Infante JR, Patel MR, Pant S, Chmielowski B, Janku F, Tapia C, Ratti N, Van Vlasselaer P, Brown GL, Hung A, Oft M, Diab A. PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma. J Clin Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
67. Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Colen RR, Carter BW, Evans E, Tawbi HAH, Karp DD, Subbiah V, Dev R, Hess KR, Ueno NT, Simon GR, Overman MJ, Coleman RL, Meric-Bernstam F. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. J Clin Oncol, 2017 ASCO Annual Meeting, 2017.
68. Sen S, Piha-Paul SA, Kato S, Karp DD, Janku F, Fu S, Pant S, Tsimberidou AM, Subbiah V, Kurzrock R, Meric-Bernstam F, Hong DS. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. J Clin Oncol, 2017 ASCO Annual Meeting, 2017.
69. Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, Mitra R, Wu S, Sood A, Coleman RL. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. J Clin Oncol, 2017 ASCO Annual Meeting, 2017.
70. Naing A, Infante JR, Wong DJL, Korn WM, Aljumaily R, Papadopoulos KA, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Van Vlasselaer P, Brown GL, Oft M, Tannir NM. Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer. J Clin Oncol, 2017 ASCO Annual Meeting, 2017.
71. Hecht JR, Falchook GS, Patel MR, Aljumaily R, Infante JR, Naing A, Wong DJL, Autio KA, Ratti N, Wainberg ZA, Bendell JC, Pant S, Brown GL, Van Vlasselaer P, Oft M, Papadopoulos KP. Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) plus FOLFOX in metastatic pancreatic adenocarcinoma (PDAC). J Clin Oncol, 2017 ASCO Annual Meeting, 2017.
72. Hecht JR, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJL, Autio KA, Wainberg ZA, Javle MM, Bendell JC, Pant S, Van Vlasselaer P, Brown GL, Oft M, Papadopoulos KP. Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). 2017 Gastrointestinal Cancers Symposium, 2017.
73. Dembla V, Ray D, Lockett P, Fullmer C, Subramanian H, Subbiah V, Fu S, Janku F, Tsimberidou AM, Naing A, Piha-Paul SA, Hong DS, Pant S, Miller VA, Lim J, Le H, Karp DD. Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) - 2011-2015: The challenge of precision medicine in a very broad playing field 68(1), 2016.
74. Naing A, Papadopoulos KP, Autio KA, Wong DJ, Patel M, Falchook G, Pant S, Ott PA, Whiteside M, Patnaik A, Mumm J, Janku F, Chan I, Bauer T, Colen R, VanVlasselaer P, Brown GL, Tannir NM, Oft M, Infante J. Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1. J Immunother Cancer; 31st Annual Meeting of the SITC 2016 4(1), 2016.
75. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. PARTNER: An Open-Label, Randomized, Phase 2 Study of Docetaxel/Cisplatin Chemotherapy With or Without Panitumumab as First-Line Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Oral Oncol 61:31-40, 2016. e-Pub 2016. PMID: 27688102.
76. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco D, Patnaik A, Bendel JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Oft M, Brown GL, Infante JR, Tannir N. Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1. Ann Oncol; Abstract Book of the 41st ESMO Congress 27(6), 2016.
77. Beeram M, Tolaney SM, Beck J, Dickler MN, Conlin AK, Dees C, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Kambhampati S, Costigan TM, Chan E, Pant S, Kalinsky K, Burris HA, Becerra CH, Rexer BN, Puhalla SL, Goetz MP. A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer 27(6), 2016.
78. Hamilton EP, Patel M, Gluck WL, Weise AM, Pant S, Fields Jones S, LoRusso P, Kittaneh M, Cosulich S, Harrington EA, Littlewood G, Oelmann EM, Burris HA. A phase I study of continuous (Con) and intermittent (Int) AZD2014 plus fulvestrant (F) in patients (pts) with estrogen receptor (ER+) metastatic breast cancer (BC). J Clin Oncol, 2016 ASCO Annual Meeting 34, 2016.
79. Dean EJ, Falchook GS, Patel MR, Brenner AJ, Infante, JR, Arkenau HT, Borazanci EH, Lopez JS, Pant S, Schmid P, Frankel AE, Fields Jones S, McCulloch W, Kemble G, O'Farrell M, Burris H. Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. 2016 ASCO Annual Meeting, 2016.
80. Chen LT, Siveke JT, Wang-Gillam A, Hubner R, Pant S, Dragovich T, Chung VM, Chang DZ, Ross PJ, Cooray P, Tebbutt NC, Franke FA, Belanger B, Dhindsa N, Jong F, Mamlouk K, Von Hoff DD. Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy. J Clin Oncology, Proceedings of the ASCO 2016 Gastrointestinal Cancers Symposium, 2016.
81. Naing A, Papadopoulos KP, Infante RJ, Lee Wong DJ, Autio KA, Ott PA, Falchook GS, Patel MR, Pant S, Patnaik A, Mumm JB, Whiteside M, Chan IH, Bendell JC, Bauer TM, Janku F, Colen RR, Tannir NM, Van Vlasselaer P, Oft M. Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1. 2016 ASCO Annual Meeting, 2016.
82. Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K, Beck JT, Gordon MS, Weiss GJ, Taylor MH, Chaves J, Mita AC, Chin KM, von Heydebreck A, Cuillerot JM, Gulley JL. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. 2016 ASCO Annual Meeting, 2016.
83. Papadopoulos KP, Naing A, Infante JR, Autio KA, Ott PA, Lee Wong DJ, Falchook GS, Patel MR, Pant S, Whiteside M, Mumm JB, Chan IH, Bendell JC, Rasco DW, Shih KC, Javle MM, Bauer TM, Colen RR, Van Vlasselaer P, Oft M. Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer. J Clin Oncol, 2016 ASCO Annual Meeting, 2016.
84. Beeram M, Tolaney SM, Beck J, Dickler MN, Conlin AK, Dees C, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Kambhampati S, Costigan TM, Chan E, Pant, S., Kalinsky K, Burris HA, Becerra CH, Rexer BN,. A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. ESMO 2016 Congress, 2016.
85. Dembla V, Ray D, Lockett P, Fullmer C, Subramanian H, Subbiah V, Fu S, Janku F, Tsimberidou AM, Naing A, Piha-Paul SA, Hong DS, Pant, S, Miller VA, Lim J, Le H, Karp DD. Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) - 2011-2015: The challenge of precision medicine in a very broad playing field. 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2016.
86. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant, S., Whiteside M, Rasco D, Patnaik A, Bendel JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Oft M, Brown GL, Infante JR, Tannir N.. Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1, 2016.
87. Brenner A, Infante J, Patel M, Arkenau H-T, Voskoboynik M, Borazanci E, Falchook G, Molife LR, Pant S, Dean E, Pelosof L, Jones S, Rubino C, McCulloch W, Zhukova-Harrill V, Kemble G, O’Farrell M, Burris HA III. First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination – final results of dose escalation. Mol Cancer Ther 14(12S), 2015.
88. 35. Infante JR, Naing A, Papadopoulos KP, Autio KA, Ott PA, Wong DJ, Falchook GS, Patel M, Pant S, Whiteside M, Bendell JC, Bauer TM, Janku F, Javle M, Colen R, Tannir N, Oft M. PEGylated human IL-10 (AM0010) in advanced solid tumors. AACR-NCI-EORTC International Conference: Mol Cancer Ther 14(12), 2015.
89. Disis ML, Patel M, Pant S, Hamilton EP, Lockhart AC, Kelly K, Thaddeus-Beck J, Gordon M, Weiss GL, Ejadi S, Taylor MH, Chin K, Cuillerot JM, Von Heydebreck A, Gulley Avelumab JA. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. The European Cancer Congress 2015 Scientific Programme. e-Pub 2015.
90. Arkenau HT, Voskoboynik M, Infante J, Brenner A, Patel M, Borazanci E, Falchook G, Molife LR, Pant S, Dean E, Pelosof L, Jones S, Rubino C, McCulloch W, Zhukova-Harrill V, Kemble G, O'Farrell M, Burris H. Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. The European Cancer Congress 2015 Scientific Programme. e-Pub 2015.
91. Voss M, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith D, Kwak EL, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel M, Neuwirth R, Zohren F, Infante J. Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. The European Cancer Congress 2015 Scientific Programme. e-Pub 2015.
92. The European Cancer Congress 2015 Scientific Programme. Effects of rifampin, a strong metabolic enzyme inducer, on the pharmacokinetics (PK) of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), in patients with advanced solid tumors or lymphomas. Zhou X, Pant S, Sarantopoulos J, Patel M, Nemunaitis J, Lockhart AC, Zhang B, Bargfrede M, Muehler A, Venkatakrishnan K. e-Pub 2015.
93. Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Lockhart AC, Goodman D, Zhang B, Dansky Ullmann C, Mould DR, Venkatakrishnan K. Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies. The European Cancer Congress 2015 Scientific Programme. e-Pub 2015.
94. Tolaney SM, Beeram M, Beck JT, Conlin AK, Dees EC, Dickler MN, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Turner PK, Cai N, Chan EM, Pant S, Becerra C, Kalinsky K, Puhalla S, Rexer BN, Burris HA, Goetz MP. A phase Ib study of abemaciclib with therapies for metastatic breast cancer. J Clin Oncol, 2015 ASCO Annual Meeting Proceedings 33(15S), 2015.
95. Infante JR, Naing A, Papadopoulos KP, Autio KA, Ott PA, Wong DJL, Falchook GS, Patel MR, Pant S, Whiteside M, Bendell JC, Bauer TM, Janku F, Javle MM, Hong DS, Oft M. A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. J Clin Oncol, 2015 ASCO Annual Meeting Proceedings 33(15S), 2015.
96. Disis ML, Patel MR, Pant S, Infante JR, Lockhart C, Kelly K, Beck JT, Gordon MS, Weiss GL, Ejadi S, Taylor MH, von Heydebreck A, Chin KM, Cuillerot J-M, Gulley JL. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. J Clin Oncol, 2015 ASCO Annual Meeting Proceedings 33(15S), 2015.
97. Moore KN, Varghese AM, Hyman DM, Callies S, Lin J, Wacheck V, Pant S, Bauer TM, Bendell JC. A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer. J Clin Oncol, 2015 ASCO Annual Meeting Proceedings 33(15), 2015.
98. Pant S, Patel MR, Kurkjian C, Hemphill MB, Flores MRC, Thompson DS, Bendell JC. A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach. J Clin Oncol, 2015 ASCO Annual Meeting Proceedings 33(15), 2015.
99. Zhou X, Nemunaitis J, Pant S, Bauer T, Lockhart A, Patel M. Zhang B, Kelly V, Ullmann CD, Bargfrede M. Venkatakrishnan K. The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomas. Proceedings of the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Eur J Cancer 50(6), 2014.
100. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel M, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Kaufman H, Lockhart AC, Tan E, Yang S, Diallo M, Scott J, Sharma S. Randomized, phase 1 crossover study assessing the bioequivalence of tablet and capsule formulations of dovitinib (TKI258). AACR Annual Meeting 2014 Proceedings, Cancer Res 74(19), 2014.
101. Osama Khawandanah M, Kurkjian C, Penaroza S, Arnold C, Herman TS, Talbert M, Postier R, Pant S. Utility of 18F-flourodeoxyglucose positron emission tomography (FDG-PET) to predict resectability after neoadjuvant therapy in patients with unresectable pancreatic cancer on CT scans. J Clin Oncol, Proceedings of the 2014 ASCO Gastrointestinal Cancers Symposium 32(3S), 2014.
102. Pant S, Hart LL, Bendell JC, Infante JR, Fields Jones S, Mohyuddin A, Murphy P, Patton j, Charles Penley W, Shelton Thompson D, Burris HA. Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors. J Clin Oncol, 2013 ASCO Annual Meeting 31(15S), 2013.
103. Wirth LJ, Dakhil SR, Kornek G, Axelrod R, Adkins D, Pant S, O’Brien PE, Debruyne PR, Oliner KS, Dong J, Bach BA. Partner: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol, Proceedings of the 2013 ASCO Annual Meeting 31(15S), 2013.
104. Bendell J, Hart LL, Pant S, Infante JR, Fields Jones S, Mohyuddin A, Murphy P, Patton J, Penley WC, Shelton Thompson D, Burris HA. Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors. J Clin Oncol, 2013 ASCO Gastrointestinal Cancers Symposium 31(4S), 2013.
105. Martin LK, Wei L, Van Loon K, Lyer RV, Pant S, Fogelman DR, Ko AH, Bekaii-Saab TS. Treatment-related hypertension (HTN) as a predictive biomarker for clinical outcomes in patients (pts) with advanced pancreas cancer (APCA) treated with bevacizumab (B): A pooled analysis of four prospective clinical trials. J Clin Oncol, 2013 ASCO Gastrointestinal Cancers Symposium 31(4S), 2013.
106. Moore KN, Fields Jones S, Kurkjian C, Arkenau H-T, Infante JR, Pant S, Burris HA, McMeekin DS, GibbonsJ, Harrow K, Liang C, Ramsey S, Bendell JC. Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012.
107. Kurkjian C, Pant S, Burris HA, Bendell JC, Fields Jones S, Moore KN, Moreno O, Mass RD, Infante JR. ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012.
108. Pant S, Fields Jones S, Kurkjian C, Infante JR, Moore KN, Burris HA, McMeeking S, Kursar JD, Zamek-Gliszczynski M, Jones E, Yuen E, Chan EM, Bendell JC. A first-in-human phase I study of the oral fNotch inhibitor LY900009 in patients with advanced cancer. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012.
109. Arkenau H-T, Infante JR, Pant S, Burris HA, McMeekin DS, Gibbons J, Harrow K, Liang C, Ramsey S, Bendell JC. The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012.
110. Srour SA, Machiorlatti M, Bhutta U, Pierson N, Cherry MA, Pant S, Thompson D, Kurkjian C. Acute myeloid leukemia: comparison of epidemiology and treatment outcomes between insured and uninsured patients. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S). e-Pub 2012.
111. Butt S, Akl P, Bhardwaj H, Srour SA, Dunn T, Pant S, Cherry MH. Patients with FLT3 negative acute myeloid leukemia and normal cytogenetic who have the combination mutations (NPM1-/CEBPA-) have better survival than patients who have the combination mutations (NPM1+/CEBPA+). Blood, ASH Annual Meeting 118(21), 2011.
112. Camacho LH, Pant S, Saleh MN, Abbadessa G, Kazakin J, Schwartz BE, Bendell JC. Phase 1b results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011.
113. Khawandanah M, Chimpiri R, Kurkjian C, Herman TS, Qubaiah OM, Postier R, Ghabach B, Thompson D, Pant S. Factors affecting resection rate in patients undergoing neoadjuvant therapy for pancreatic cancer. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S). e-Pub 2011.
114. Hopps S, Borders E, Medina P. Moorman M, Webb R, Kurkjian C, Pant S. Incidence and risk factors of cetuximab-induced hypersensitivity infusion reactions (HIRs). J Clin Oncol, 2011 ASCO Annual Meeting 29(15S). e-Pub 2011.
115. Hopps S, Borders E, Medina P. Moorman M, Webb R, Kurkjian C, Pant S. Incidence and risk factors of cetuximab-induced hypersensitivity infusion reactions (HIRs). J Clin Oncol, 2011 ASCO Annual Meeting 29(15S). e-Pub 2011.
116. Pant S, Saleh M, Bendell J, Abbadessa G, Kazakin J, Chen C, Schwartz B, Camacho LH. Phase 1b dose escalation trial evaluating c-Met inhibitor ARQ 197 and Gemcitabine in patients (pts) with advanced solid tumors on schedules refined by in vitro mechanistic studies. Book of the 35th European Society of Medical Oncology (ESMO) Congress, Ann Oncol 21(8S), 2010.
117. Pant S, Hostetter G, Armstrong B, Bittner M, Shack S, Savage S, Weiss GJ, Ozer H, Ramanathan R. Use of independent genome-wide assays to discover HOXA signature in colon and rectal cancers and validate a role in tumorigenesis. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings 27(15S). e-Pub 2009.
118. Pant S, Armstrong B, Hostetter G, Weiss GJ, Ozer H, Ramanathan R. Colon and rectal cancer gene expression profiles: Results from the analysis of samples in Expression Project for Oncology (expO) database. ASCO Meeting Library, 2009 Gastrointestinal Cancers Symposium. e-Pub 2009.
119. Pant S, Hamadani SM, Crilley P, Szer J, Dodds AJ, Stevenson DE, Phillips G, Elder P, Nivison-Smith I, Avalos B, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan E. Incidence of late failure following myeloablative conditioning with BuCy2 and matched sibling allogeneic stem cell transplantation for acute myeloid leukemia. Blood 112(11), 2008.
120. Pant S, Crilley PA, Dodds AJ, Szer J, Bolwell BJ, Elder P, Styler M, Kalaycio M, Sobecks R, Nivison-Smith I, Avalos BR, Copelan EA. Long-term follow-up of treatment for acute myeloid leukemia with allogeneic hematopoetic cell transplantation using BuCy2 as preparation. Blood 108(11), 2006.
121. Kojouri K, Pant S, Kamble R, Sylvester-Kohrt N, Selby GB, Ozer H, Kharfan-Dabaja MA. Significance of elevated serum lactate dehydrogenase (LDH) in patients undergoing salvage autologous bone marrow/peripheral stem cell transplantation (BM/PSCT) for relapsed/refractory Hodgkin’s lymphoma (R/R-HL). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23(16S), 2005.
122. Pant S, Venkatappa S, Sethi S, Lightfoot S, Tfayli A, Ozer H. Male breast cancer: molecular pathology and demographics of a case series. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22(14S), 2004.

Books (edited and written)

1. Daniel D. Karp, Gerald S. Falchook, Joann Lim, Shubham Pant. Handbook of Targeted Cancer Therapy and Immunotherapy. 2. Wolters Kluwer: Houston Texas, 2018.